Eckert & Ziegler to Acquire CIS bio Afterloader Business
Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement.
Eckert & Ziegler to Acquire CIS bio Afterloader Business Berlin, 21.11.2003.
Eckert & Ziegler AG, a specialist for therapeutic radiation sources, has received an option from CIS bio international (Paris, France) to acquire its afterloader business. The proposed transactions, to become effec- tive in January 2004, covers all assets of the Curietron product family, including the newly certified Curietron C device, and of a number of brachytherapy sources for the treatment of cancer. The acquired business areas will be managed by Eckert & Ziegler's subsidiaries in Berlin and Prague. "The acquisition enhances our product portfolio for the radiation oncologist, and adds to our customer base", commented Dr. Andreas Eckert, Chief Executive Officer of the group. "It is a first success in our efforts to broaden the growth potential of Eckert & Ziegler through the acquisition of selected and profitable niche business. We consequently expect the acquisition to not burden our bottom line." Afterloaders are medical devices used for the treatment of cancers. Eckert & Ziegler Strahlen- und Medizintechnik is a public company (ISIN DE 0005659700) acting as a holding for number of subsidiaries involved in isotope manufacturing. CIS bio international is a subsidiary of Schering S.A., France.
The Executive Board
For further questions please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0) 30 / 94 10 84-138
http://www.ezag.de
end of ad-hoc-announcement
(c)DGAP 21.11.2003
WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 210917 Nov 03
Eckert & Ziegler to Acquire CIS bio Afterloader Business Berlin, 21.11.2003.
Eckert & Ziegler AG, a specialist for therapeutic radiation sources, has received an option from CIS bio international (Paris, France) to acquire its afterloader business. The proposed transactions, to become effec- tive in January 2004, covers all assets of the Curietron product family, including the newly certified Curietron C device, and of a number of brachytherapy sources for the treatment of cancer. The acquired business areas will be managed by Eckert & Ziegler's subsidiaries in Berlin and Prague. "The acquisition enhances our product portfolio for the radiation oncologist, and adds to our customer base", commented Dr. Andreas Eckert, Chief Executive Officer of the group. "It is a first success in our efforts to broaden the growth potential of Eckert & Ziegler through the acquisition of selected and profitable niche business. We consequently expect the acquisition to not burden our bottom line." Afterloaders are medical devices used for the treatment of cancers. Eckert & Ziegler Strahlen- und Medizintechnik is a public company (ISIN DE 0005659700) acting as a holding for number of subsidiaries involved in isotope manufacturing. CIS bio international is a subsidiary of Schering S.A., France.
The Executive Board
For further questions please contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Phone: +49 (0) 30 / 94 10 84-138
http://www.ezag.de
end of ad-hoc-announcement
(c)DGAP 21.11.2003
WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart 210917 Nov 03